Clinical infrastructure specialist Feedback plc (AIM: FDBK) announced on Wednesday that it is collaborating with Vertex In Healthcare, a clinical IT firm with operations in the UK, UAE and South Africa. This agreement aims to combine technologies and resell products, driving commercial opportunities in multiple markets. The collaboration outlines the terms for future definitive commercial agreements.
Vertex, a registered UK reseller of the MedDream medical image viewer by UAB Softneta, brings regulatory approvals (FDA Cleared and CE Marked) across the USA, Middle East and Europe. Feedback will integrate the MedDream viewer into Bleepa, enhancing its teleradiology offerings and enabling direct sales to Radiologists for primary diagnostic reporting services. This integration will expand Feedback's reach into key markets like the USA and the Middle East, while maintaining a primary focus on India.
The partnership allows Feedback and Vertex to resell each other's products, facilitating rapid and cost-effective expansion into new territories. Bleepa's integration into Vertex's solutions will help increase market share across various customer segments.
As part of the agreement, Vertex will license Feedback's legacy picture archiving communication system, Cadran PACS, with the MedDream Viewer. This will help build a PACS proposition initially targeted at South Africa and other international markets, including the UK, generating licensing royalties for Feedback.
Feedback's products, Bleepa and CareLocker, enhance clinician access to patient data and facilitate remote clinical team collaboration. Bleepa displays clinical results from CareLocker, enabling secure, auditable dialogue among clinicians. This model supports flexibility for clinicians and seamless patient movement between providers.
Feedback's SaaS-based model targets growth across the NHS, veterinary markets and private healthcare providers, anticipating increased revenue visibility as its customer base expands.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024